Cholangiocarcinoma: Has there been any progress?

Canadian Journal of Gastroenterology

Volumn 24, Issue 1, 2010, Pages 52-57

  Meza Junco, Judith ^a   Montano Loza, Aldo J ^b   Ma, Mang ^b   Wong, Winnie ^b   Sawyer, Michael B ^a   Bain, Vincent G ^b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cholangiocarcinoma; Liver transplant; Neoadjuvant chemoradiation; Primary sclerosing cholangitis

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TUMOR MARKER;

ADJUVANT THERAPY; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIGITAL IMAGING; DISTANT METASTASIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT CONTRAINDICATION;

EID: 77951239211     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/704759     Document Type: Review

References (57)

1. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008;12:131-150
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357 (Pubitemid 32496970)
3. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol 2004;40:472-477 (Pubitemid 38230849)
4. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-125
5. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615
6. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-526 (Pubitemid 38524134)
7. Bergquist A, Ekbom A, Olsson R. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327 (Pubitemid 34194790)
8. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42.
9. Yachimski P, Pratt DS. Cholangiocarcinoma: Natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42:178-190
10. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004;24:139-154
11. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005;50:1734-1740 (Pubitemid 41203674)
12. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865-869
13. Steinberg W. The clinical utility of the CA 19-9 tumor associated antigen. Am J Gastroenterol 1990;85:350-355 (Pubitemid 20140602)
14. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(Suppl 6):1-9. (Pubitemid 35216840)
15. Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006;11:913-922
16. Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004;24:155-164
17. Brugge WR. Endoscopic techniques to diagnose and manage biliary tumors. J Clin Oncol 2005;23:4561-4565
18. Kim JY, Kim MH, Lee TY, et al. Clinical role of (18) F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: A prospective study compared with conventional imaging. Am J Gastroenterol 2008;102:1-7.
19. Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:57-65. (Pubitemid 350267250)
20. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999;31:305-309 (Pubitemid 29229369)
21. Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: Evaluation of specific cytomorphologic features and CA 19-9 levels. Am J Clin Pathol 2005;124:355-360
22. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006;45:568-574 (Pubitemid 44307380)
23. Lee JG, Leung JW, Baillie J, Layfield LJ, Cotton PB. Benign, dysplastic, or malignant - making sense of endoscopic bile duct brush cytology: Results in 149 consecutive patients. Am J Gastroenterol 1995;90:722-726
24. Xing GS, Geng JC, Han XW, Dai JH, Wu CY. Endobiliary brush cytology during percutaneous transhepatic cholangiodrainage in patients with obstructive jaundice. Hepatobiliary Pancreat Dis Int 2005;4:98-103.
25. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214-219 (Pubitemid 38293308)
26. Moreno-Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-1072 (Pubitemid 44498705)
27. Moreno-Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2006;12:S15-9.
28. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004;99:1675-1681 (Pubitemid 39237490)
29. Fleming ID, Cooper JS, Hensen DE, et al. AJCC (American Joint Committee on Cancer) cancer staging manual, 5th edn. Philadelphia: Lippincott-Raven, 1998.
30. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: Is transplantation an option? For whom? J Hepatol 2007;47:455-459
31. Launois B, Campion JP, Brissot P, Gosselin M. Carcinoma of the hepatic hilus. Surgical management and the case for resection. Ann Surg 1979;190:151-157
32. Launois B, Terblanche J, Lakehal M, et al. Proximal bile duct cancer: High resectability rate and 5-year survival. Ann Surg 1999;230:266-275 (Pubitemid 30191894)
33. Nagorney DM, Kendrick ML. Hepatic resection in the treatment of hilar cholangiocarcinoma. Adv Surg 2006;40:159-171 (Pubitemid 44648288)
34. Yeh CN, Jan YY, Yeh TS, Hwang TL, Chen MF. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol 2004;11:606-611
35. Ohtsuka M, Ito H, Kimura F. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002;89:1525-1531 (Pubitemid 35404319)
36. De Oliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-762 (Pubitemid 46684105)
37. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma: A 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005;31:533-539 (Pubitemid 40724095)
38. Pichlmayr R, Weimann A, Klempnauer J, et al. Surgical treatment in proximal bile duct cancer: A single-center experience. Ann Surg 1996;224:628-638 (Pubitemid 26384886)
39. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001;193:384-391 (Pubitemid 32895979)
40. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517 (Pubitemid 32946713)
41. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) 2005;7:278-282 (Pubitemid 43878475)
42. Dingle BH, Rumble RB, Brouwers MC. Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: A systematic review. Can J Gastroenterol 2005;19:711-716
43. Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canadian experience. Liver Transpl 2005;11:1412-1416 (Pubitemid 43071591)
44. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single-center experience. Ann Surg 1997;225:472-483
45. Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008;12:117-122
46. Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998;187:358-364 (Pubitemid 28467610)
47. Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83-88
48. Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997;185:429-436 (Pubitemid 27475441)
49. Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: Analysis of a single-center experience and review of the literature. Liver Transpl 2001;7:1023-1033 (Pubitemid 34023989)
50. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000;69:1633-1637
51. Robles R, Figueras J, Turrión VS. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004;239:265-271 (Pubitemid 38176362)
52. Sudan D, DeRoover A, ChinnaKotla S, et al. Radiochemotherapy and transplantation allow long-term survival for non-metastatic hilar cholangiocarcinoma. Am J Transplantation 2002;2:774-779 (Pubitemid 36342621)
53. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-461
54. Yang L, Yan L. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol 2008;14:6289-6297
55. Sotiropoulos GC, Kaiser GM, Lang H, et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: A single-center experience. Transplant Proc 2008;40:3194-3195 (Pubitemid 350085264)
56. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006;82:1703-1707
57. Neuhaus P, Jonas S, Settmacher U, et al. Surgical management of proximal bile duct cancer: Extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003;388:194-200. (Pubitemid 36987711)